Christophe dombu
Stock Analyst at Kepler Capital
(0.11)
# 4,585
Out of 4,651 analysts
185
Total ratings
37.8%
Success rate
-12%
Average return
Main Sectors:
Stocks Rated by Christophe dombu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNN Smith & Nephew | Downgraded: Hold | n/a | $29.81 | - | 1 | Jun 4, 2026 | |
| LON: 0QBO Coloplast A/S | Initiated Coverage: Buy | kr 482.00 | kr 429.70 | +12.17% | 1 | May 20, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €810.00 | €730.50 | +10.88% | 33 | May 7, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Sell | €23.50 | €23.90 | -1.67% | 19 | May 7, 2026 | |
| LON: SN Smith & Nephew plc | Maintained: Buy | 1,462p | 1,096p | +33.39% | 5 | May 6, 2026 | |
| EPA: VIRP Virbac SA | Maintained: Buy | €415.00 | €332.50 | +24.81% | 6 | Apr 17, 2026 | |
| SWX: KURN Kuros Biosciences AG | Maintained: Buy | CHF 38.00 | CHF 21.90 | +73.52% | 9 | Apr 14, 2026 | |
| SWX: BSLN Basilea Pharmaceutica AG | Maintained: Buy | CHF 69.00 → CHF 70.00 | CHF 53.10 | +31.83% | 27 | Apr 13, 2026 | |
| LON: 0HNZ Fagron NV | Maintained: Buy | €27.50 | €22.45 | +22.49% | 2 | Apr 9, 2026 | |
| EPA: MAAT MaaT Pharma SA | Maintained: Buy | €17.00 | €2.89 | +488.24% | 26 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €14.30 | €4.53 | +215.67% | 25 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.62 | +649.73% | 26 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | €0.10 → €0.01 | €0.81 | n/a | 5 | Feb 7, 2025 |
Smith & Nephew
Jun 4, 2026
Downgraded: Hold
Price Target: n/a
Current: $29.81
Upside: -
Coloplast A/S
May 20, 2026
Initiated Coverage: Buy
Price Target: kr 482.00
Current: kr 429.70
Upside: +12.17%
argenx SE
May 7, 2026
Maintained: Buy
Price Target: €810.00
Current: €730.50
Upside: +10.88%
Lakefront Biotherapeutics NV
May 7, 2026
Maintained: Sell
Price Target: €23.50
Current: €23.90
Upside: -1.67%
Smith & Nephew plc
May 6, 2026
Maintained: Buy
Price Target: 1,462p
Current: 1,096p
Upside: +33.39%
Virbac SA
Apr 17, 2026
Maintained: Buy
Price Target: €415.00
Current: €332.50
Upside: +24.81%
Kuros Biosciences AG
Apr 14, 2026
Maintained: Buy
Price Target: CHF 38.00
Current: CHF 21.90
Upside: +73.52%
Basilea Pharmaceutica AG
Apr 13, 2026
Maintained: Buy
Price Target: CHF 69.00 → CHF 70.00
Current: CHF 53.10
Upside: +31.83%
Fagron NV
Apr 9, 2026
Maintained: Buy
Price Target: €27.50
Current: €22.45
Upside: +22.49%
MaaT Pharma SA
Mar 31, 2026
Maintained: Buy
Price Target: €17.00
Current: €2.89
Upside: +488.24%
Mar 26, 2026
Maintained: Buy
Price Target: €14.30
Current: €4.53
Upside: +215.67%
Mar 20, 2026
Maintained: Buy
Price Target: $12
Current: $1.62
Upside: +649.73%
Feb 7, 2025
Downgraded: Sell
Price Target: €0.10 → €0.01
Current: €0.81
Upside: n/a